Jazz Drug Patent Portfolio

Jazz owns 3 orange book drugs protected by 26 US patents Given below is the list of Jazz's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11426373 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 19 Sep, 2037
Active
US10213400 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US10864181 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US11253494 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US8772306 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US9050302 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US9486426 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
Active
US10213400 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US10864181 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US11253494 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US11986446 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US8772306 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US9050302 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US9486426 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
Active
US10195168 Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders 11 Jan, 2033
Active
US10675258 Method of using gamma-hydroxybutyrate compositions for the treatment of disorders 11 Jan, 2033
Active
US11554102 Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders 11 Jan, 2033
Active
US8591922 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
Active
US8901173 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
Active
US9132107 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
Active
US7763615 Ecteinascidin analogs for use as antitumour agents 13 Dec, 2029
Active
US8731963 Sensitive drug distribution system and method 17 Jun, 2023 Expired
US8731963 Sensitive drug distribution system and method 17 Dec, 2022 Expired
US6024981 Rapidly dissolving robust dosage form 09 Apr, 2018 Expired
US6221392 Rapidly dissolving robust dosage form 09 Apr, 2018 Expired
US6106861 Multiparticulate tablet disintegrating in less than 40 seconds in the mouth 05 Dec, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Jazz.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 29 May, 2024 US10864181
Payment of Maintenance Fee, 8th Year, Large Entity 24 Apr, 2024 US9486426
Payment of Maintenance Fee, 4th Year, Large Entity 22 Nov, 2023 US10675258
Patent Term Extension Certificate 17 Oct, 2023 US7763615
Electronic Review 06 Jun, 2023 US7763615
Notice of Final Determination -Eligible 15 May, 2023 US7763615
Payment of Maintenance Fee, 8th Year, Large Entity 01 Mar, 2023 US9132107
Notice of Final Determination -Eligible 25 Jan, 2023 US7763615
Recordation of Patent Grant Mailed 17 Jan, 2023 US11554102
Patent Issue Date Used in PTA Calculation 17 Jan, 2023 US11554102
Email Notification 29 Dec, 2022 US11554102
Issue Notification Mailed 28 Dec, 2022 US11554102
Application Is Considered Ready for Issue 13 Dec, 2022 US11554102
Dispatch to FDC 13 Dec, 2022 US11554102
Issue Fee Payment Verified 12 Dec, 2022 US11554102


Jazz's Drug Patent Litigations

Jazz's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 06, 2015, against patent number US8772306. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Jazz Pharmaceutical, Inc. as the respondent. Click below to track the latest information on how companies are challenging Jazz's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8731963 September, 2015 Final Written Decision
(22 Mar, 2017)
Jazz Pharmaceuticals, Inc. Par Pharmaceutical, Inc. et al.
US8772306 February, 2016 Terminated-Denied
(28 Jul, 2016)
Jazz Pharmaceutical, Inc. Amneal Pharmaceuticals LLC
US8772306 October, 2015 Terminated-Settled
(23 May, 2016)
Jazz Pharmaceutical, Inc. Ranbaxy, Inc.
US9050302 March, 2016 Terminated-Denied
(23 May, 2016)
Jazz Pharmaceuticals Ireland Limited RANBAXY INC
US8772306 October, 2015 Terminated-Denied
(12 Apr, 2016)
Jazz Pharmaceutical, Inc. Par Pharmaceutical, Inc.


Jazz Drug Patents' Oppositions Filed in EPO

Jazz drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 23, 2018, by Hoffmann Eitle. This opposition was filed on patent number EP14709858A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17200764A Sep, 2020 Ter Meer Steinmeister & Partner Patentanwälte mbB Granted and Under Opposition
EP17200764A Sep, 2020 Hexal AG Granted and Under Opposition
EP17200764A Sep, 2020 Zentiva, k.s. Granted and Under Opposition
EP17200764A Mar, 2020 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Granted and Under Opposition
EP14709858A Aug, 2018 Hexal AG Revoked
EP14709858A Aug, 2018 Ter Meer Steinmeister & Partner Patentanwälte mbB Revoked
EP14709858A Jul, 2018 Hoffmann Eitle Revoked


Jazz's Family Patents

Jazz drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 24.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Jazz Drug List

Given below is the complete list of Jazz's drugs and the patents protecting them.


1. Fazaclo Odt

Fazaclo Odt is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6024981 Rapidly dissolving robust dosage form 09 Apr, 2018
(6 years ago)
Expired
US6221392 Rapidly dissolving robust dosage form 09 Apr, 2018
(6 years ago)
Expired
US6106861 Multiparticulate tablet disintegrating in less than 40 seconds in the mouth 05 Dec, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fazaclo Odt's drug page


2. Xywav

Xywav is protected by 22 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11426373 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 19 Sep, 2037
(12 years from now)
Active
US10213400
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US10864181
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US11253494
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US8772306
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US9050302
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US9486426
(Pediatric)
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Sep, 2033
(8 years from now)
Active
US10213400 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US10864181 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US11253494 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US11986446 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US8772306 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US9050302 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US9486426 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters 15 Mar, 2033
(8 years from now)
Active
US10195168 Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US10675258 Method of using gamma-hydroxybutyrate compositions for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US11554102 Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US8591922 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US8901173 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US9132107 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders 11 Jan, 2033
(8 years from now)
Active
US8731963
(Pediatric)
Sensitive drug distribution system and method 17 Jun, 2023
(1 year, 3 months ago)
Expired
US8731963 Sensitive drug distribution system and method 17 Dec, 2022
(1 year, 9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xywav's drug page


3. Zepzelca

Zepzelca is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7763615 Ecteinascidin analogs for use as antitumour agents 13 Dec, 2029
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepzelca's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Jazz News

Legal action required for Jazz and Hikma to address allegations of 'reverse payment' related to narcolepsy medication - XM

27 Aug, 2024

Jazz Pharmaceuticals and Hikma Pharmaceuticals to address allegations of 'reverse payment' concerning narcolepsy medication - Westlaw Today

27 Aug, 2024

See More